Psoriasis is a chronic, immune-mediated skin condition. It causes red, scaly, itchy, often inflamed patches. Because the ...

With all that in mind, if you have $2,000 available to invest that isn't needed for monthly bills, to pay down short-term ...

The global psoriasis burden shows a slight increase from 1990 to 2021 and is projected to rise further by 2050.

J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.

Arcutis aims to expand its market reach with new approvals. Management recently pleased the market with its sales guidance ...

Investing.com -- Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock rose 4.5% on Monday after the FDA accepted the company’s application to expand the use of its psoriasis treatment to younger children.

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in child ...

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical ...

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three ...

These companies have exceptional dividend track records. AbbVie is moving on from its Humira patent losses, and its portfolio benefits from some exceptionally profitable products. Johnson & Johnson is ...

Icotronkinra results in significantly higher incidence of complete skin clearance at week 16 than placebo. HealthDay News — For adults and adolescents with moderate-to-severe plaque psoriasis, ...

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remissionOver $500M cash ...